• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jeffrey A. Engelman, MD, PhD

Publications

  • Katayama R, Aoyama A, Yamori T, Qi J, Oh-Hara T, Song Y, Engelman JA, Fujita N.Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition.Cancer Res. 2013 Apr 18.
    23598276
  • Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W.Characteristics of Lung Cancers Harboring NRAS Mutations.Clin Cancer Res. 2013 Apr 18.
    23515407
  • Coffee EM, Faber AC, Roper J, Sinnamon M, Goel G, Keung L, Wang WV, Vecchione L, Devriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE.Concomitant BRAF and PI3K/mTOR Blockade is Required for Effective Treatment of BRAFV600E Colorectal Cancer.Clin Cancer Res. 2013 Apr 2.
    23549875
  • Shaw AT, Engelman JA.ALK in lung cancer: past, present, and future.J Clin Oncol. 2013 Mar 10;31(8):1105-11.
    23401436
  • Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, Engelman JA.Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.Cancer Cell. 2013 Jan 14;23(1):121-8.
    23245996
  • Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ.FGFR1 amplification in squamous cell carcinoma of the lung.J Thorac Oncol. 2012 Dec;7(12):1775-80.
    23154548
  • Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, Tannous BA, Eichler AF, Fukumura D, Engelman JA, Jain RK.Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3119-27.
    23071298
  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012 Oct;13(10):1011-9.
    22954507
  • Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W.Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33.
    22773810
  • Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, Padera R, Engelman JA, Jänne PA, Shapiro GI, Shimamura T, Wong KK.Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.Cancer Res. 2012 Jul 1;72(13):3302-11.
    22552292
  • Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA.MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.Cancer Res. 2012 Jul 1;72(13):3228-37.
    22552284
  • Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA.Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors.Sci Transl Med. 2011 Mar 23;3(75):75ra26.
    21430269
  • Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, Sequist LV.Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.Oncologist. 2011;16(3):319-26.
    21339258
  • Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH.Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors.Clin Cancer Res. 2011 Mar 1;17(5):1131-1139.
    21220471
  • Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Jänne PA, Engelman JA.Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.Cancer Res. 2011 Feb 1;71(3):1081-91.
    21266357
  • Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA.BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.Sci Signal. 2010;3(149):ra84.
    21098728
  • Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R.Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer.J Clin Oncol. 2010 Nov 20;28(33):4953-60.
    20940188
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010 Oct 28;363(18):1693-703.
    20979469
  • Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV.EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.Neuro Oncology. 2010 Nov;12(11):1193-9.
    20627894
  • Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S.Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.Br J Cancer. 2010 Sep 28;103(7):1025-33.
    20808308
  • Engelman JA, Cantley LC.Chemoprevention meets glucose control.Cancer Prev Res (Phila Pa). 2010 Sep;3(9):1049-52.
    20810671
  • Turke AB, Engelman JA.PIKing the right patient.Clin Cancer Res. 2010 Jul 15;16(14):3523-5.
    20538763
  • Ryan DP, Engelman JA, Ferrone CR, Sahani DV, Lisovsky M.Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.N Engl J Med. 2010 Jun 24;362(25):2411-9.
    20573930
  • Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, García-Echeverría C, Bardeesy N, Sharpless NE, Hayes ND, Kim WY, Engelman JA, Wong KK.Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.Cancer Cell. 2010 Jun 15;17(6):547-59.
    20541700
  • Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC.Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.Cancer Res. 2010 Jun 1;70(11):4709-18.
    20484037
  • Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.EMBO Mol Med. 2010 May;2(5):146-58.
    20432502
  • Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA.Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.Oncogene. 2010 Apr 22;29(16):2346-56.
    20118985
  • Faber AC, Wong KK, Engelman JA.Differences underlying EGFR and HER2 oncogene addiction.Cell Cycle. 2010 Mar 1;9(5):851-2.
    20160489
  • Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK.An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation.Cancer Res. 2010 Mar 15;70(6):2485-94.
    20215504
  • Courtney KD, Corcoran RB, Engelman JA.The PI3K pathway as drug target in human cancer.J Clin Oncol. 2010 Feb 20;28(6):1075-83. Review.
    20085938
  • Wong KK, Engelman JA, Cantley LC.Targeting the PI3K signaling pathway in cancer.Curr Opin Genet Dev. 2010 Feb;20(1):87-90. Review.
    20006486
  • Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.Cancer Cell. 2010 Jan 19;17(1):77-88.
    20129249
  • Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.J Clin Oncol. 2010 Jan 10;28(2):357-60.
    19949011
  • Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK, Engelman JA.Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8.
    19850869
  • Engelman JA.Targeting PI3K signalling in cancer: opportunities, challenges and limitations.Nat Rev Cancer. 2009 Aug;9(8):550-62. Review.
    19629070
  • Naumov GN,Nilsson MB,Cascone T,Briggs A,Straume O,Akslen LA,Lifshits E,Byers LA,Xu L,Wu HK,Janne P,Kobayashi S,Halmos B,Tenen D,Tang XM,Engelman J,Yeap B,Folkman J,Johnson BE,Heymach JV.Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.Clin Cancer Res. 2009 May 15;15(10):3484-94.
    19447865
  • Sequist LV,Engelman JA,Lynch TJ.Toward noninvasive genomic screening of lung cancer patients.J Clin Oncol. 2009 Jun 1;27(16):2589-91.
    19414671
  • Ogino S,Nosho K,Kirkner GJ,Shima K,Irahara N,Kure S,Chan AT,Engelman JA,Kraft P,Cantley LC,Giovannucci EL,Fuchs CS.PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.J Clin Oncol. 2009 Mar 20;27(9):1477-84.
    19237633
  • Rexer BN,Engelman JA,Arteaga CL.Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.Cell Cycle. 2009 Jan 1;8(1):18-22. Review.
    19106609
  • Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garca-Echeverra C, Weissleder R, Mahmood U, Cantley LC, Wong KK.Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.Nat Med. 2008 Dec;14(12):1351-6.
    19029981
  • Rothenberg SM,Engelman JA,Le S,Riese DJ 2nd,Haber DA,Settleman J.Modeling oncogene addiction using RNA interference.Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4.
    18711136
  • Koivunen JP,Mermel C,Zejnullahu K,Murphy C,Lifshits E,Holmes AJ,Choi HG,Kim J,Chiang D,Thomas R,Lee J,Richards WG,Sugarbaker DJ,Ducko C,Lindeman N,Marcoux JP,Engelman JA,Gray NS,Lee C,Meyerson M,Janne PA.EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Clin Cancer Res. 2008 Jul 1;14(13):4275-83.
    18594010
  • Lynch TJ Jr,Blumenschein GR Jr,Engelman JA,Espinoza-Delgado I,Govindan R,Hanke J,Hanna NH,Heymach JV,Hirsch FR,Janne PA,Lilenbaum RC,Natale RB,Riely GJ,Sequist LV,Shapiro GI,Shaw A,Shepherd FA,Socinski M,Sorensen AG,Wakelee HA,Weitzman A.Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12.
    18520291
  • Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA.Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.J Clin Invest. 2008 Jul;118(7):2609-19.
    18568074
  • Engelman JA, Settleman J.Acquired resistance to tyrosine kinase inhibitors during cancer therapy.Curr Opin Genet Dev. 2008 Feb;18(1):73-9. Review.
    18325754
  • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations.J Clin Oncol. 2008 May 20;26(15):2442-9.
    18458038
  • Engelman JA,Janne PA.Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Clin Cancer Res. 2008 May 15;14(10):2895-9. Review.
    18483355
  • Engelman JA, Cantley LC.A sweet new role for EGFR in cancer.Cancer Cell. 2008 May;13(5):375-6.
    18455118
  • Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jnne PA.PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.Cancer Res. 2007 Dec 15;67(24):11924-32.
    18089823
  • Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL.Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.Clin Cancer Res. 2007 Aug 15;13(16):4909-19.
    17699871
  • Engelman JA.The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4637-40. Review.
    17671156
  • Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS.Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4583-8.
    17671145
  • Lee JY, Engelman JA, Cantley LC.Biochemistry. PI3K charges ahead.Science. 2007 Jul 13;317(5835):206-7.
    17626872
  • Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jnne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK.Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.Cancer Cell. 2007 Jul;12(1):81-93.
    17613438
  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jnne PA.MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling.Science. 2007 May 18;316(5827):1039-43.
    17463250
  • Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrs AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jnne PA.Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR -amplified lung cancer.J Clin Invest. 2006 Oct;116(10):2695-706.
    16906227
  • Engelman JA, Cantley LC.The Role of the ErbB Family Members in Non-Small Cell "Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors".Clin Cancer Res. 2006 Jul 15;12(14):4372s-6s. Review.
    16857813
  • Engelman JA, Luo J, Cantley LC.The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.Nat Rev Genet. 2006 Aug;7(8):606-19. Review.
    16847462
  • Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS.Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.Cancer Res. 2005 Dec 1;65(23):10992-1000.
    16322248
  • Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jnne PA.Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94.
    16106023
  • Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC.The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex.J Cell Biol. 2005 Aug 1;170(3):455-64.
    16043515
  • Shimamura T, Lowell AM, Engelman JA, Shapiro GI.Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.Cancer Res. 2005 Jul 15;65(14):6401-8.
    16024644
  • Jnne PA, Engelman JA, Johnson BE.Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.J Clin Oncol. 2005 May 10;23(14):3227-34.
    15886310
  • Engelman JA, Jnne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93.
    15731348
  • Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC.Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice.Mol Cell Biol. 2005 Mar;25(5):1596-607.
    15713620